Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)

NCT03524092 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03524092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03524092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
October 19, 2018
Completion date
February 17, 2025
Enrollment
1,328 (actual)
Sites
385

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis